COH.AX

COH.AX maintains a strong liquidity position with a current ratio of 2.35 and a price-to-book ratio of 3.29, indicating a solid balance sheet and reasonable valuation. The company's return on equity of 19.94% and return on assets of 13.77% suggest efficient use of equity and assets, outperforming the industry median for both metrics. The company's profitability is supported by a gross profit margin of 73.75% and an operating margin of 22.10%, which are both above the industry median, indicating strong cost control and pricing power. COH.AX's revenue is primarily concentrated in its core medical equipment and supplies segment, with no significant geographic diversification reported in the latest financial data. Looking ahead, COH.AX is projected to experience moderate revenue growth, with a price-to-earnings ratio of 16.48 and a price-to-revenue ratio of 2.72, suggesting the market expects continued earnings growth. The company's free cash flow of 98.5 million AUD and capital expenditure of -102.6 million AUD indicate a focus on maintaining and expanding its operational capacity. The risk assessment for COH.AX indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.12 suggests a conservative capital structure with minimal leverage. Recent filings and transcripts do not highlight any significant operational or strategic changes that would impact the company's financial performance in the near term.